GT Biopharma Inc

GTBP

Latest QuantConomy context for GTBP: asset profile, market coverage, scored signals, and source-linked SEC insider filings when available.

Asset class

stock

Primary venue

NASDAQ

Recent signals

SEC filings

Asset profile

QuantConomy has a structured record for GTBP. More descriptive asset metadata will appear here when the platform record includes it.

Latest signal rows

Recent signals for GTBP

Scored rows are pulled from the same signal API used by the digests.

Signal	Direction	Score	Observed	Reason
fundamental eps change	very bullish	76	May 15, 12:00 AM	GTBP (Q1 2026, diluted eps): EPS grew 98.4% ($-6.68 → $-0.11). [sequential period basis, very bullish signal]
corporate event bylaws change	neutral	40	Jun 12, 08:50 PM	GTBP filed 8-K: Articles/Bylaws Amendment - [weak neutral signal]
corporate event delisting	very bearish	75	May 22, 12:05 PM	GTBP filed 8-K: Delisting Notice - 1 material event - [strong very bearish signal]

FUNDAMENTAL signals are experimental: the generator was recently enabled and coverage is still being validated.

Market	Exchange	Source	Asset record
GTBP	NASDAQ	alpaca	GT Biopharma, Inc. Common Stock
GTBP	NASDAQ	fmp	GT Biopharma, Inc.
GTBP	NASDAQ	alphavantage	GT Biopharma Inc

Buys, last 90d

Sells, last 90d

Rows

No recent Form 3, 4, or 5 insider transaction rows were returned for GTBP.

Source: SEC filings via QuantConomy. Not investment advice.

Get the data

These rows come from the QuantConomy signal, asset, market, and SEC filings API surfaces, also available to AI agents over MCP.